Ultragenyx Pharmaceutical | RARE - Current Liabilities

Stock Price
24.71
Daily Change
0.64 2.66%
Monthly
6.92%
Yearly
-43.09%
Q1 Forecast
23.33

Ultragenyx Pharmaceutical reported $340.02M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Agios Pharmaceuticals USD 74.76M 4.35M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Insmed USD 417.21M 105.53M Sep/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Kyowa Hakko Kirin JPY 185.16B 7.26B Sep/2025
MacroGenics USD 44.47M 5.47M Sep/2025
Moderna USD 1.68B 109M Sep/2025
Neurocrine Biosciences USD 638M 91.7M Sep/2025
PTC Therapeutics USD 866.24M 238.44M Sep/2025
Regeneron Pharmaceuticals USD 4.43B 758.1M Sep/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 4.48B 336.9M Sep/2025